Why communication is important for your project?

Simple….

If you want to be successful you need to

Communicate your results

Disseminate your outputs

We are here to help you as a multiplier…if you keep us in the loop!
Which material does the IMI office rely upon

- Periodic and final reports: importance of high quality publishable summary
- Project website: ideally it should be the “one stop shop”
- Publications (open access)
- Slide decks
- Interim reviews
- Close out meetings
Communication of science and technology results

All starts from the data….the importance of quality in research

Can We Trust Our Data?

Most Scientists Experienced Failure to Reproduce

- 90% of scientists think there is a crisis

Baker, Nature 533, 2016

N = 1,576 scientists
Communication of project results to feed IMI progress analysis and reporting

<table>
<thead>
<tr>
<th>IMI PROGRESS ANALYSES</th>
</tr>
</thead>
<tbody>
<tr>
<td>Socio-economic impacts of IMI projects</td>
</tr>
<tr>
<td>Read the associated press release</td>
</tr>
<tr>
<td>- IMI’s added value - project outputs linked to early socio-economic impacts (Autumn 2015)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Bibliometric analyses of ongoing projects</th>
</tr>
</thead>
<tbody>
<tr>
<td>News article</td>
</tr>
<tr>
<td>- Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking (Seventh Report: May 2016)</td>
</tr>
<tr>
<td>News article</td>
</tr>
<tr>
<td>- Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking (Sixth Report: June 2015)</td>
</tr>
<tr>
<td>Executive Summary</td>
</tr>
<tr>
<td>- Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking (Fifth Report: December 2014)</td>
</tr>
<tr>
<td>- Bibliometric analysis of ongoing projects: Innovative Medicines Initiative Joint Undertaking (First Report: October 2012)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other reports and documents</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Draft Code of Practice on Secondary Use of Medical Data in Scientific Research Projects</td>
</tr>
<tr>
<td>This document, written by representatives of the IMI office and IMI projects, aims to provide a set of harmonised rules applicable to secondary use of medical data. It is intended to be useful to research projects involving multiple legal entities established in one or more EU Member States.</td>
</tr>
<tr>
<td>- Report - Patient involvement in IMI projects from Calls 1 to 6</td>
</tr>
<tr>
<td>- Report - Patients’ awareness of IMI and views of patient involvement in research</td>
</tr>
</tbody>
</table>

IMI projects are successful in publishing impactful results!
How do we use your communication outputs and why the are very valuable for us

- Feed IMI KPI
- Material for IMI Success stories
- Feed the Table of projects outputs
- Presentations to IMI Advisory Bodies
- Presentations to the IMI Governing Board
- Presentations to Policy makers
- IMI communication material
- IMI website
IMI – Ecosystem for innovative collaborations

IMI is a **neutral platform** where **all involved** in drug development can engage in **open collaboration** on **shared challenges**.

All partners needed to find transformative solutions to **reduce late stage attrition, speed patient access** and **improve health outcomes** and find solutions for a sustainable healthcare system.

KPI nr 7: Co-authorships and cross-sector publications between European researchers on IMI2 projects (sectors include academia, small and mid-sized companies, pharma, regulators, patient organisations, etc.).
Measures of success

- New model developed & published
- Setting new standards
- In house implementation by industry
- Impact on regulatory practice
- Better drugs and impact on medical practice

COMMUNICATION & DISSEMINATION
News, Achievements, Success Stories

Projects & results

PROJECT FACTSHEETS
Learn more about our projects, including their goals, funding, participants, and latest news and results.

SUCCESS STORIES FROM PROJECTS
In-depth stories about some of our project successes, including interviews with project coordinators.

MAPS AND STATISTICS
Our projects have partners across Europe and beyond. Find them with the help of this interactive tool.

CATALOGUE OF PROJECT TOOLS
Accelerate your own research. Have a look at the list of accessible tools generated by our projects.
Contribute to the catalogue of project tools
We want your success stories!

Support for patients with respiratory diseases

13/03/2019

IMI’s PRO-active project has developed new patient-centred tools and approaches to help people with chronic obstructive respiratory disease (COPD) get more personalised treatments - a means to boost their activity levels, health and well-being.

COPD affects 1 in 10 of all people aged 50 and over and is a leading cause of death. The disease is characterised by breathlessness, coughing and often excessive mucus production, all of which make any physical activity uncomfortable and difficult for sufferers. In Europe alone, some 300,000 Europeans die each year from COPD.

Physical inactivity is a key predictor of death in patients with COPD. The IMI project PRO-active has developed new tools to help researchers and clinicians measure the impact of the disease on patients’ experiences with physical activity and the physical difficulties patients encounter. This information can now be used to assess the impact of effective treatments on an outcome that is directly relevant to patients.

‘Lack of physical activity is an indicator of mortality,’ says project coordinator Thierry Troosters of the Katholieke Universiteit Leuven in Belgium. ‘Patients with COPD who drop their physical activity levels are more likely to die than people who maintain those levels. We could already measure physical activity, but now we have a tool that captures how patients experience it.’

The new tools are providing doctors, nurses and other healthcare workers and researchers with unique information on the effect of treatment on their patients, he adds. They will also feed into the way new medicines and other interventions are assessed and benchmarked, based on patients’ experiences.

A focus on patient experience

By combining wearable physical activity monitors with short daily surveys, researchers found an effective way to gauge symptom-related stress experienced when patients were active. Three different kinds of activity monitors were trialled to find the most sensitive ones, which are best suited for people with chronic diseases.

Input from patients was key to the development of the PRO-active tool. COPD sufferers themselves designed the user-friendly questions for the surveys and patient organisations were also given important managerial roles on the ethics committee board of the project.

‘We want to get insights from the patients’ perspective on how an intervention benefits them directly,’ says Troosters, explaining how normally treatment testing focuses on physiological results, but not patient experiences.
We need you to be a success! Let us know timely your good news!!

Success stories from projects

2018

A faster way to spot the tell-tale signs of cancer-causing drugs
06/06/2018
IMI’s MARCAR project has identified potential biomarkers that could indicate how likely a drug is to cause cancer at an earlier stage of testing than is currently possible, which could save drug companies time and money - and lead to safer drugs reaching patients faster.

‘The benefits of collaboration come through loud and clear’ – an interview with the GETREAL project coordinator
20/05/2018
GETREAL developed new tools and resources for incorporating real-life data into drug development, which could increase confidence in new medicines and help get them to patients more quickly. In an interview with the IMI Programme Office, project coordinator, Elaine Irving of Glassfiche/Kline explains the main project achievements, and why they wouldn’t have been possible without IMI.

‘Tapping the full potential of Europe’s health data
17/04/2018
IMI’s EMIF project is helping researchers tap into Europe’s treasure trove of electronic health data, saving them time and money in their quest to cure and develop better drugs for debilitating diseases. The effort has already led to promising findings linked to Alzheimer’s and obesity.

‘We made significant breakthroughs’ – an interview with the PREDECT project coordinators
16/04/2018
IMI’s PREDECT project developed new, much-improved laboratory models of cancer, which could improve the accuracy with which pharmaceutical companies predict the effectiveness of new drugs. In an interview the IMI Programme Office, project coordinator John Hickman of Servier, and academic coordinator Emmy Verschueren of the Institute for Molecular Medicine Finland at the University of Helsinki, explain the project’s most significant breakthroughs, and how these achievements will help in the future search for new drugs.

‘We made significant accomplishments in a very challenging field’ – an interview with MIP-DILI project coordinators
03/04/2018
IMI’s MIP-DILI project deepened the knowledge of the science behind drug-induced liver injury (DILI) and improved laboratory tests in use to predict DILI in the early stages of drug development. In an interview with the IMI Programme Office, Richard Weaver of Servier and academic coordinator, Kevin Park of the University of Liverpool, describe the project’s most important achievements, and explain how they are already benefiting industry, academia, and patients, while at the same time reducing the use of animals in research.